Download - Formulating Institutional Antibiotic Policy
![Page 1: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/1.jpg)
Formulating Institutional Antibiotic
PolicyMARY ANN D. LANSANG, MD, FPCP, FPSMID
PHICS 23RD ANNUAL CONVENTION
MAY 19, 2017
![Page 2: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/2.jpg)
OutlineContext: global and local actions; the infection control unit and the
antimicrobial stewardship program of an institution
Why: the need for an institutional antibiotic policy
How: evidence-guided recommendations, best practices, and
experiences in the formulation of antibiotic policies in an
institution
Who: stewards of rational antibiotic use and stakeholders
![Page 3: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/3.jpg)
![Page 4: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/4.jpg)
The Development of Antimicrobial ResistanceFrom: Faces of Antimicrobial Resistance, IDSA, 2017
![Page 5: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/5.jpg)
2020 Targets of the Action Plan (5-year time frame)
- Reduce by 30% carbapenem-resistant Enterobacteriaceae infections acquired during hospitalization
-Maintain the prevalence of ceftriaxone-resistant N. gonorrhoeae to zero
-Reduce by at least 30% MRSA bloodstream infections compared to 2014 rates
-Reduce by 30% MDR Pseudomonas spp. Infections acquired during hospitalization compared to 2014 rates
- Reduce by 25% ciprofloxacin-resistant non-typhoidalSalmonella infections compared to 2014
![Page 6: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/6.jpg)
November 14 – 20, 2016
![Page 7: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/7.jpg)
![Page 8: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/8.jpg)
WHO Global Priority Pathogens Listfor R&D of New Antibiotics (released 27 Feb 2017)
# Mycobacteria not included – already established as a global priority.
![Page 9: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/9.jpg)
WHO Global Priority Pathogens Listfor R&D of New Antibiotics
![Page 10: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/10.jpg)
WHO Global Priority Pathogens Listfor R&D of New Antibiotics
![Page 11: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/11.jpg)
Yearly resistance rates of E. coli to ceftriaxone, gentamicin and imipenem
ARSP, 2006 - 2015
2015 carbapenem resistance rates: Ertapenem: 4.2% (n=3,036); Imipenem: 3.5% (n=6,132);
Meropenem: 3.4% (n=5,794)
![Page 12: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/12.jpg)
Yearly resistance rates of K. pneumoniae to carbapenems
ARSP, 2006 - 2015
Imipenem: 2014 = 6.9%; 2015 = 11.1%; Meropenem: 2014 = 7.6%; 2015 = 11.9%;
Ertapenem: 2014 = 10%; 2015 = 15.3%
![Page 13: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/13.jpg)
Yearly resistance rates of S. aureusARSP, 2006-2015
MRSA rate for bloodstream infections, 2015: 60.25% (n=570)
![Page 14: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/14.jpg)
From: Philippine Action Plan to Combat Antimicrobial Resistance, 2015
![Page 15: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/15.jpg)
“… the concerted implementation of systematic,
multi-disciplinary, multi-pronged interventions
in both public and private hospitals in the
Philippines to improve appropriate use of
antimicrobials…”
![Page 16: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/16.jpg)
Strategies for controlling AMR:inter-related approaches
Antibiotic
stewardship
• Surveillance
• Antibiotic policies &
guidelines
• Antibiotic manage-
ment programs
Prevention of spread
• Infection prevention &
control in healthcare settings
• Isolation when needed
• Hand hygiene
• Environmental hygiene
Reduction
• Usage control
• Appropriate use
• Human
• Animal
• Environmental
![Page 17: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/17.jpg)
Core elements of the DOH AMS Program
![Page 18: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/18.jpg)
Strategies for controlling AMR:inter-related approaches
Antibiotic
stewardship
• Surveillance
• Antibiotic policies
& guidelines
• Antibiotic manage-
ment programs
Prevention of spread
• Infection prevention &
control in healthcare settings
• Isolation when needed
• Hand hygiene
• Environmental hygiene
Reduction
• Usage control
• Appropriate use
• Human
• Animal
• Environmental
![Page 19: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/19.jpg)
OutlineContext: global and local actions; the infection control unit and the
antimicrobial stewardship program of an institution
Why: the need for an institutional antibiotic policy
How: evidence-guided recommendations, best practices, and
experiences in the formulation of antibiotic policies in an
institution
Who: stewards of rational antibiotic use and stakeholders
![Page 20: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/20.jpg)
Why do we need a hospital antibiotic policy? (1)• High level of antibiotic use in hospitals. CDC report (MMWR, 7Mar2017):
• 56% of patients discharged from 323 US hospitals received antibiotics• 37% of antibiotic prescribing could be improved
• Patients with multiple pathogens are concentrated in hospitals
• Close proximity of patients with multiple healthcare worker contacts
• Sicker, more vulnerable patients in the hospitals
• Transfer of patients with MDR organisms into the hospital from the
community, another facility, or another country
![Page 21: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/21.jpg)
From: Paterson DL. The Role of Antimicrobial Management Programs in Optimizing Antibiotic Prescribing within HospitalsClin Infect Dis. 2006;42(Supplement_2):S90-S95. doi:10.1086/499407
![Page 22: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/22.jpg)
Why do we need a hospital antibiotic policy? (2)• To improve patient outcomes through appropriate antibiotic use: the RIGHT indication, choice, dose, route of administration, timing, duration
• To minimize harm to the patients (and future patients)
• To reduce health care-related costs: shorter hospital stay, use of less costly antibiotics, less ADRs
• To prevent or control the emergence of AMR
![Page 23: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/23.jpg)
OutlineContext: global and local actions; the infection control unit and the
antimicrobial stewardship program of an institution
Why: the need for an institutional antibiotic policy
How: evidence-guided recommendations, best
practices, and experiences in the formulation of
antibiotic policies in an institution
Who: stewards of rational antibiotic use and stakeholders
![Page 24: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/24.jpg)
Hospital antibiotic policy
development cycle
![Page 25: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/25.jpg)
Ideal organizational structure for the AMS program
![Page 26: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/26.jpg)
![Page 27: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/27.jpg)
From:
![Page 28: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/28.jpg)
From:
All hospitals should have a hospital antibiotic
policy to promote rational antimicrotial
prescribing and dispensing practices.
![Page 29: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/29.jpg)
From:
![Page 30: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/30.jpg)
![Page 31: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/31.jpg)
![Page 32: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/32.jpg)
![Page 33: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/33.jpg)
![Page 34: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/34.jpg)
![Page 35: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/35.jpg)
From:
All hospitals should adopt or adapt to their local
context the National Antibiotic Guidelines to
guide clinicians in the management of infectious
diseases and in the selection of the most
appropriate antimicrobial agent.
![Page 36: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/36.jpg)
![Page 37: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/37.jpg)
![Page 38: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/38.jpg)
![Page 39: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/39.jpg)
From:
Simple and clear clinical pathways
should be created to guide and
standardize treatment for timely
and appropriate management of
infections.
![Page 40: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/40.jpg)
Example of clinical pathway: Severe sepsis(from The Medical City)
![Page 41: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/41.jpg)
Summary of strategies to improve antibiotic use (1)Pulcini & Gryssens. Virulence 2013; 4:192-202
Passive educational measures Developing/updating local antibiotic guidelines
Educational sessions, workshops, local conferences
Clinical rounds discussing cases
Active interventions Prospective audit with intervention & feedback
Reassessment of abtic prescriptions, with streamlining &
de-escalation of therapy
Academic detailing, educational outreach visits
Restrictive measures Limiting no. of abtics on the hosp. formulary
Antibiotic order form (compulsory)
Automatic stop order
Formulary restriction & pre-authorization
Limiting reporting of susceptibilities by the micro lab
Regulating contacts with the pharma industry
![Page 42: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/42.jpg)
Summary of strategies to improve antibiotic use (2)Pulcini & Gryssens. Virulence 2013; 4:192-202
Supportive/supplemental measures Multidisciplinary AMS team
Consultancy service (infectious diseases, pharmacy,
microbiology)
Computer-assisted management program
Parenteral to oral conversion
Therapeutic drug monitoring service
![Page 43: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/43.jpg)
Carrot or stick approach toimproving antibiotic use?
![Page 44: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/44.jpg)
Carrot or stick approach toimproving antibiotic use?
![Page 45: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/45.jpg)
Positive
Clinical
Impact
Positive
Financial
Impact
Political
Expediency
Resource
Requirements
Ease of
Implementation
0 = None
5 = High
0 = None
5 = High
0 = Impossible
5 = Win/Win
0 = Impossible
5 = None
0 = Impossible
5 = Easy
Prioritize potential interventions
![Page 46: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/46.jpg)
OutlineContext: global and local actions; the infection control unit and the
antimicrobial stewardship program of an institution
Why: the need for an institutional antibiotic policy
How: evidence-guided recommendations, best
practices, and experiences in the formulation of
antibiotic policies in an institution
Who: stewards of rational antibiotic use and
stakeholders
![Page 47: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/47.jpg)
Ideal organizational structure for the AMS program
![Page 48: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/48.jpg)
Clinicians/
Prescribers
Patients
Patient’s
relatives
Public? PhilHealth?
![Page 49: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/49.jpg)
DOH timelines for selected core elements of the AMS Program
![Page 50: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/50.jpg)
2015 WHO WPRO and Philippines partnership: Pilot AMS Program implementation in Hospitals
TRAINING OF TRAINORS
WORKSHOP ON THE
ANTIMICROBIAL STEWARDSHIP
ADVOCACY PACKAGE
(March and September 2015)
Baguio General Hospital and Medical
Center
CAR
Jose B. Lingad Memorial Regional
Hospital
Region III
Rizal Medical Center NCR
Research Institute for Tropical Medicine NCR
Corazon Locsin Montelibano Memorial
Regional Hospital
Region VI
Vicente Sotto Memorial Medical Center Region VII
Northern Mindanao Medical Center Region X
Southern Philippines Medical Center Region XI
![Page 51: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/51.jpg)
![Page 52: Formulating Institutional Antibiotic Policy](https://reader031.vdocument.in/reader031/viewer/2022021923/5a66da1c7f8b9a21208b4b6d/html5/thumbnails/52.jpg)